RenovoRx, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
This is RenovoRx's quarterly report for the period ending June 30, 2026, filed August 13, 2026. The filing header provides basic SEC submission metadata (accession number, filing date, document count) and company identification (CIK 0001574094, Mountain View CA address, pharmaceutical SIC code). No specific financial results, transaction details, counterparties, dollar amounts, share counts, or business changes are evident from the filing metadata alone.
Why this rating
Routine quarterly SEC filing with no disclosed material events, transactions, or financial data in the metadata; standard periodic disclosure.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.